Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Pembrolizumab e Blinatumomab nel trattamento di partecipanti con leucemia linfoblastica acuta ricorrente o refrattaria

26 ottobre 2026 aggiornato da: City of Hope Medical Center

Uno studio di fase 1/2 di pembrolizumab in combinazione con blinatumomab in pazienti con leucemia linfoblastica acuta recidivante/refrattaria

This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such as pembrolizumab and blinatumomab, may interfere with the ability of tumor cells to grow and spread.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. Assess the safety and tolerability of combination immunotherapy with blinatumomab and pembrolizumab by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase 1) II. Determine the recommended phase 2 schedule of combination immunotherapy with pembrolizumab and blinatumomab. (Phase 1) III. Evaluate the anti-leukemia activity of combination immunotherapy blinatumomab and pembrolizumab as assessed by overall response rate (complete response [CR] or CR with incomplete recovery [CRi]). (Phase 2)

SECONDARY OBJECTIVES:

I. Estimate time to response (CR or CRi) and response duration. (Phase 2) II. Estimate overall survival and event-free survival. (Phase 2) III. Determine the number and proportion of patients who underwent hematopoietic stem cell transplantation (HSCT) after treatment of pembrolizumab and blinatumomab. (Phase 2) IV. Determine the number and proportion of patients who receive pembrolizumab maintenance and the proportion continuing for up to 1 year. (Phase 2) V. Estimate the minimal residual disease rate. (Phase 2)

CORRELATIVE OBJECTIVES:

I. Explore evolution of T cell subsets at various points in treatment (T naive, T effector, T effector memory, T central memory, CD4, CD8). (Phase 2) II. Evaluate PD-L1 expression levels on acute lymphoblastic leukemia (ALL) blasts and blasts counts overtime. (Phase 2) III. Evaluate PD-1/PD-L1 expression on subsets of T cells. (Phase 2) IV. Evaluate the clonal evolution of leukemic blasts in response to treatment. (Phase 2)

OUTLINE:

Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.

After completion of study treatment, participants are followed up at 30 days and then every 3 months for 1 year.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

26

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Duarte, California, Stati Uniti, 91010
        • City of Hope Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Previously treated ALL including philadelphia chromosome (BCR-Ab1) positive ALL who meet all of the following criteria:

    • Diagnosis of CD19-positive B-cell ALL based on the flow cytometry and histology
    • Previously treated subjects with primary refractory disease OR after first or subsequent relapse
    • Subjects with detectable lymphoblasts in bone marrow (BM) or extramedullary disease (EMD) that is radiographically measurable and amenable to repeat biopsies
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

  • Left ventricular ejection fraction (LVEF) > 45%

  • Pulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for hemoglobin) > 50% predicted

  • Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 ml/min for subject with creatinine levels > 1.5 X institutional ULN

  • Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases

  • Albumin >= 2.5 mg/dL

  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants

  • Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants

  • Beta human chorionic gonadotropin (beta HCG) negative

  • Human immunodeficiency virus (HIV): negative HIV antibody / polymerase chain reaction (PCR)

  • Hepatitis B virus (HBV): negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR

  • Hepatitis C virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)

  • Required screening laboratory data (within 28 days prior to administration of pembrolizumab)

  • Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or investigational therapy) for the treatment of cancer as follows:

    • At least 1 week or 5 half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy

    • Exceptions or modifications to the above are as follows:

      • Medications that are typically part of a maintenance therapy for ALL, such as glucocorticoids or mercaptopurine, may be administered up to 3 days prior to the first dose, except vinca alkaloids which must be discontinued at least 14 days prior to the start of study treatment; TKIs are not permitted to be continued at screening (e.g. Gleevec)
    • Intrathecal (IT) chemotherapy may be dosed up to 7 days prior to first dose of pembrolizumab (cytarabine [Ara-C] recommended)

    • For biologics (e.g. monoclonal antibodies), washout period of 1 month beyond the recommended dosing interval and at least 4 weeks or 5 half-lives (whichever is longer) since the last dose

  • All acute toxic effects of any prior antitumor therapy must be resolved to grade =< 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)

  • For female subjects of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of contraception from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab; a negative serum pregnancy test is required for female subjects at screening; lactating females must agree to discontinue nursing before administration of study drugs

  • For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs

  • In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's ALL

  • Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions; psychological, social, familial or geographical factors that might preclude adequate study participation should be considered

  • Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures

Exclusion Criteria:

  • Diagnosis of mature B-cell ALL (Burkitt's leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)

  • A life threatening illness, medical condition or organ system dysfunction which, in the investigators' opinion, could compromise the subject's safety or interfere with the absorption or metabolism of pembrolizumab

  • Active or symptomatic central nervous system (CNS) disease

    • For study purposes, a subject will not be considered as having active CNS disease if the subject has documentation of prior CNS disease and has received prior treatment (IT or radiation) and is:

      • Asymptomatic for the last 28 days prior to screening and
      • Has documented at least 2 negative cerebrospinal fluid (CSF) cytology (which must include 1 lumbar puncture [LP] within the study screening window)
  • Uncontrolled undercurrent illness including but not limited to unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements; subjects with active infection are permitted to enroll provided that the infection is documented to be under control

  • History of myelodysplastic syndrome or organ transplantation

  • History of non-lymphoid malignancy except for the following:

    • Adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requirement only hormonal therapy and with normal prostate specific antigen for > 1 year prior to the start of pembrolizumab, or any other cancer that has been in complete remission without treatment for >= 5 years prior to enrollment
  • Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab

  • Ongoing drug-induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), HIV, alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, or portal hypertension

  • Prior allogeneic bone marrow transplantation

  • Pregnancy or breastfeeding

  • Has known history of, or any evidence of active, non-infectious pneumonitis

  • Concurrent participation in an investigational drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study

  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent

    • Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
    • Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment

  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab

  • Has received a live vaccine within 30 days of planned start of study therapy

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (pembrolizumab, blinatumomab)

Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.

Correlative studies

Given IV

Altri nomi:
  • Blincyto
  • Anticorpo monoclonale bispecifico anti-CD19 x anti-CD3
  • Anticorpo monoclonale bispecifico ricombinante MT103 anti-CD19/Anti-CD3
  • MEDI-538
  • MT-103

Given IV

Altri nomi:
  • Chiavetruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Dose-Limiting Toxicity (Phase 1)
Lasso di tempo: From the start of initial treatment up to 35 days

Number of participants experiencing at least one dose-limiting toxicity (DLT) during the DLT assessment period. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

From the start of initial treatment up to 35 days
Response Rate (Phase 2)
Lasso di tempo: From the start of initial treatment till the end of protocol treatment, up to 5 cycles

Response was defined as complete response (CR)/CR with incomplete hematologic recovery (CRi) based on the National Comprehensive Cancer Network guidelines on acute lymphoblastic leukemia version 1 2017 response criteria.

From the start of initial treatment till the end of protocol treatment, up to 5 cycles

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Grade 3-5 Adverse Events
Lasso di tempo: From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.

Toxicities were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. Number of participants experiencing at least one Grade 3, 4, or 5 adverse event.

From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.
Duration of Remission
Lasso di tempo: From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.

Duration of remission is defined as the time from first documented complete response (CR) or complete response with incomplete hematologic recovery (CRi) to the earliest of disease progression or the end of protocol follow-up.

From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.
Time to Response
Lasso di tempo: From date of first dose of study drug up to the end of study treatment

Time to response is defined as the time from the first dose of study treatment to the first documented objective response (complete response [CR] or complete response with incomplete hematologic recovery [CRi]).

From date of first dose of study drug up to the end of study treatment
Median Overall Survival
Lasso di tempo: From date of first dose of study drug up to 1 year

Overall survival is defined as the time from first dose of study treatment to death from any cause. Median overall survival was estimated using the Kaplan-Meier method

From date of first dose of study drug up to 1 year
Incidence of Relapse
Lasso di tempo: From date of first dose of study drug up to 1 year

Incidence of relapse is defined as the number of participants who experienced disease relapse after achieving a documented response (complete response [CR] or complete response with incomplete hematologic recovery [CRi]) during the protocol-defined follow-up period.

From date of first dose of study drug up to 1 year
Allogeneic Stem Cell Transplantation (SCT) Realization Rate
Lasso di tempo: From the end of study treatment through 1 year.

Allogeneic stem cell transplantation (SCT) realization rate was measured by number and proportion of patients who underwent SCT after treatment of pembrolizumab and blinatumomab.

From the end of study treatment through 1 year.
Number and Proportion of Patients Who Start Pembrolizumab Maintenance
Lasso di tempo: Up to 1 year
Up to 1 year
Number and Proportion of Patients Who Complete Pembrolizumab Maintenance
Lasso di tempo: Up to 1 year
Up to 1 year
Minimal Residual Disease Rate
Lasso di tempo: From the end of study treatment through 1 year.

Minimal residual disease (MRD) was measured by number and proportion of patients with CR/CRi who had confirmed minimal residual disease.

From the end of study treatment through 1 year.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Lihua Budde, City of Hope Medical Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

2 agosto 2019

Completamento primario (Effettivo)

31 gennaio 2025

Completamento dello studio (Stimato)

29 settembre 2027

Date di iscrizione allo studio

Primo inviato

5 aprile 2018

Primo inviato che soddisfa i criteri di controllo qualità

19 aprile 2018

Primo Inserito (Effettivo)

30 aprile 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

26 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 19017
  • 19017 (Altro identificatore: City of Hope Medical Center)
  • NCI-2018-00526 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi